TARA
NASDAQProtara Therapeutics Inc.
Website
News25/Ratings6
News · 26 weeks55-33%
2025-10-262026-04-19
Mix2090d
- Insider6(30%)
- Other6(30%)
- SEC Filings5(25%)
- Earnings1(5%)
- Analyst1(5%)
- Offering1(5%)
Latest news
25 items- SECSEC Form PRE 14A filed by Protara Therapeutics Inc.PRE 14A - Protara Therapeutics, Inc. (0001359931) (Filer)
- INSIDERSEC Form 4 filed by Zummo Jacqueline4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
- INSIDERSEC Form 4 filed by Zummo Jacqueline4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
- SECProtara Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Protara Therapeutics, Inc. (0001359931) (Filer)
- SECSEC Form 10-K filed by Protara Therapeutics Inc.10-K - Protara Therapeutics, Inc. (0001359931) (Filer)
- SECProtara Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Protara Therapeutics, Inc. (0001359931) (Filer)
- PRProtara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business UpdateReported interim data from ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC); TARA-002 demonstrated 68% complete response rate at six months in BCG-Unresponsive patients Company expects to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 2H 2026 On track to initiate the ADVANCED-3 registrational trial in BCG-Naïve patients in 2H 2026 Received Breakthrough Therapy and Fast Track designations for TARA-002 in lymphatic malformations (LMs); regulatory update expected in 1H 2026 Expect to report interim results from THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on long-term parenteral support in 2H 2026 Co
- SECSEC Form 424B7 filed by Protara Therapeutics Inc.424B7 - Protara Therapeutics, Inc. (0001359931) (Filer)
- ANALYSTAnalyst initiated coverage on Protara Therapeutics with a new price targetAnalyst initiated coverage of Protara Therapeutics with a rating of Overweight and set a new price target of $27.00
- SECSEC Form SCHEDULE 13G filed by Protara Therapeutics Inc.SCHEDULE 13G - Protara Therapeutics, Inc. (0001359931) (Subject)
- SECProtara Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Protara Therapeutics, Inc. (0001359931) (Filer)
- PRTARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder CancerFavorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events Company expects to complete enrollment of the BCG-Unresponsive cohort of the ADVANCED-2 trial in 2H 2026 Company to host conference call and webcast tomorrow at 8:00 a.m. ET NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced updated interim results from its ongoing Phase 2 open-label ADVANCED-2 trial assessing intravesical TARA-002, the Company's investigational cell-based therapy, in patients with high-risk Non-Muscle Inva
- PRProtara Therapeutics to Participate in Upcoming Investor ConferencesNEW YORK, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in the following investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference. A fireside chat will take place virtually on Thursday, February 26 at 2:40 pm ET.TD Cowen 46th Annual Health Care Conference. A fireside chat will take place on Tuesday, March 3 at 2:30 pm ET in Boston. A live webcast of the events can be accessed by visiting the Events and Presentations section of the Company's website: https://ir.protaratx.com. The
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Protara Therapeutics Inc.SCHEDULE 13G/A - Protara Therapeutics, Inc. (0001359931) (Subject)
- SECSEC Form 424B7 filed by Protara Therapeutics Inc.424B7 - Protara Therapeutics, Inc. (0001359931) (Filer)
- PRProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA) ("Protara" or the "Company"), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to one newly-hired employee. The Compensation Committee of Protara's Board of Directors approved an aggregate of 10,200 stock option awards and 5,100 RSU awards to one new employee from the Inducement Plan, as inducements material to the new employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4). Such option awards were granted on February 2, 20
- INSIDERChief Financial Officer Fabbio Patrick covered exercise/tax liability with 3,261 shares, decreasing direct ownership by 5% to 64,115 units (SEC Form 4)4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
- INSIDERVP, Controller Fry Hannah covered exercise/tax liability with 1,457 shares, decreasing direct ownership by 3% to 42,723 units (SEC Form 4)4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
- INSIDERCEO and President Shefferman Jesse covered exercise/tax liability with 8,732 shares, decreasing direct ownership by 0.85% to 1,021,832 units (SEC Form 4)4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
- INSIDERChf Scientific Operations Off Zummo Jacqueline covered exercise/tax liability with 3,724 shares, decreasing direct ownership by 3% to 118,559 units (SEC Form 4)4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
- INSIDERCEO and President Shefferman Jesse covered exercise/tax liability with 16,322 shares, decreasing direct ownership by 2% to 1,030,564 units (SEC Form 4)4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
- INSIDERChf Scientific Operations Off Zummo Jacqueline covered exercise/tax liability with 6,578 shares, decreasing direct ownership by 5% to 122,283 units (SEC Form 4)4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
- INSIDERChief Financial Officer Fabbio Patrick covered exercise/tax liability with 3,063 shares, decreasing direct ownership by 4% to 67,376 units (SEC Form 4)4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
- INSIDERVP, Controller Fry Hannah covered exercise/tax liability with 2,132 shares, decreasing direct ownership by 5% to 44,180 units (SEC Form 4)4 - Protara Therapeutics, Inc. (0001359931) (Issuer)
- PRProtara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers SymposiumNEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (NASDAQ:TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that updated interim data from the cohort of BCG-Unresponsive non-muscle invasive bladder cancer (NMIBC) patients in the ongoing Phase 2 ADVANCED-2 trial of TARA-002 will be featured at the upcoming American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place from February 26, 2026 to February 28, 2026 in San Francisco. The poster presentation will include updated safety and efficacy data from approximately 25 six-month evaluable BCG-Unresponsive N